## Nasdaq Regulation



William Slattery, CFA Vice President Listing Qualifications

By Electronic Mail

October 22, 2020

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549

**Division of Corporation Finance:** 

This is to certify that on October 22, 2020 The Nasdaq Stock Market LLC (the "Exchange") received from Eucrates Biomedical Acquisition Corp. (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following securities:

Units, each consisting of one ordinary share, no par value, and one-third of one Warrant
Ordinary shares, no par value
Warrants, each whole warrant exercisable for one ordinary share at an exercise price of \$11.50 per share

We further certify that the securities described above have been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

William Stattery